Table 1

Serological follow-up of patients with trichomoniasis

Patient (N)OD ratio (sample/control)
Months
012345
12.01 (+)2.171.631.600.951.03 (−)
21.89 (+)1.982.831.943.591.27 (−)
32.64 (+)4.573.356.952.552.94 (+)
41.54 (+)1.540.900.970.950.97 (−)
52.90 (+)4.28ND1.331.271.09 (−)
62.29 (+)1.211.251.181.120.84 (−)
72.16 (+)1.921.871.801.731.73 (+)
82.23 (+)1.891.731.761.820.88 (−)
91.34 (+)1.301.361.370.97ND
101.38 (+)1.41ND0.99ND0.90 (−)
111.35 (+)1.39ND0.98NDND
122.43 (+)2.041.010.71NDND
131.37 (+)1.12ND0.95NDND
141.70 (+)0.960.86NDND0.98 (−)
151.97 (+)1.75NDND0.900.84 (−)
161.35 (+)1.26NDND1.110.94 (−)
171.51 (+)NDND1.090.990.94 (−)
181.63 (+)1.130.980.95NDND
  • Eighteen positive women were followed up for 5 months after diagnosis and anti-trichomonas therapy administration; sera were harvested monthly and tested in ELISA to detect anti-Trichomonas vaginalis IgG class antibodies. Results are shown as an OD ratio of samples (mean values of duplicates) and controls (mean value of 20 children sera). >1.28 OD: positive (in bold), <1.28 and >1.186 borderline and <1.186 negative. (+), PCR positive; (−), PCR negative; ND, not detected.